argenx SE (ARGX)
372.80
+4.20
(+1.14%)
USD |
NASDAQ |
Apr 26, 16:00
372.83
+0.03
(+0.01%)
After-Hours: 20:00
argenx Enterprise Value: 18.98B for April 26, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 26, 2024 | 18.98B |
| April 25, 2024 | 18.73B |
| April 24, 2024 | 19.11B |
| April 23, 2024 | 19.11B |
| April 22, 2024 | 18.74B |
| April 19, 2024 | 18.23B |
| April 18, 2024 | 18.12B |
| April 17, 2024 | 18.58B |
| April 16, 2024 | 18.85B |
| April 15, 2024 | 19.18B |
| April 12, 2024 | 19.29B |
| April 11, 2024 | 19.38B |
| April 10, 2024 | 19.52B |
| April 09, 2024 | 19.60B |
| April 08, 2024 | 19.75B |
| April 05, 2024 | 19.77B |
| April 04, 2024 | 19.76B |
| April 03, 2024 | 20.45B |
| April 02, 2024 | 20.37B |
| April 01, 2024 | 20.38B |
| March 28, 2024 | 20.17B |
| March 27, 2024 | 20.46B |
| March 26, 2024 | 20.40B |
| March 25, 2024 | 20.45B |
| March 22, 2024 | 20.70B |
| Date | Value |
|---|---|
| March 21, 2024 | 20.36B |
| March 20, 2024 | 17.99B |
| March 19, 2024 | 18.13B |
| March 18, 2024 | 18.26B |
| March 15, 2024 | 18.84B |
| March 14, 2024 | 19.27B |
| March 13, 2024 | 19.46B |
| March 12, 2024 | 19.83B |
| March 11, 2024 | 19.65B |
| March 08, 2024 | 19.82B |
| March 07, 2024 | 19.87B |
| March 06, 2024 | 19.99B |
| March 05, 2024 | 19.87B |
| March 04, 2024 | 19.97B |
| March 01, 2024 | 20.15B |
| February 29, 2024 | 19.36B |
| February 28, 2024 | 20.40B |
| February 27, 2024 | 21.21B |
| February 26, 2024 | 21.15B |
| February 23, 2024 | 21.11B |
| February 22, 2024 | 20.90B |
| February 21, 2024 | 20.54B |
| February 20, 2024 | 20.27B |
| February 16, 2024 | 20.04B |
| February 15, 2024 | 20.11B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
2.990B
Minimum
Oct 08 2019
28.91B
Maximum
Sep 15 2023
13.73B
Average
13.31B
Median
Aug 18 2021
Enterprise Value Benchmarks
| TC BioPharm (Holdings) PLC | 1.751M |
| Adaptimmune Therapeutics PLC | 118.40M |
| Merus NV | 2.273B |
| NuCana PLC | -13.49M |
| Biophytis SA | 2.351M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -99.17M |
| Revenue (Quarterly) | 406.84M |
| Total Expenses (Quarterly) | 543.67M |
| EPS Diluted (Quarterly) | -1.69 |
| Gross Profit Margin (Quarterly) | 90.30% |
| Profit Margin (Quarterly) | -24.38% |
| Earnings Yield | -1.38% |
| Normalized Earnings Yield | -1.471 |